Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids
NCT ID: NCT01293396
Last Updated: 2021-06-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2010-06-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes
NCT01697631
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
NCT01467323
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
NCT00824668
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers
NCT01707160
A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.
NCT00283218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Biphasic Insulin Aspart 30
35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
Insulin Aspart 30
Patients received biphasic insulin aspart 30 before breakfast and before lunch.
Biphasic Insulin Aspart 70
35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
Insulin Aspart 70
Patients received biphasic insulin aspart 70 before breakfast and before lunch.
Insulin Aspart
35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
Insulin Aspart
Patients received insulin aspart before breakfast and before lunch.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin Aspart
Patients received insulin aspart before breakfast and before lunch.
Insulin Aspart 30
Patients received biphasic insulin aspart 30 before breakfast and before lunch.
Insulin Aspart 70
Patients received biphasic insulin aspart 70 before breakfast and before lunch.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 27 kg/m2
* age 35 to 75 years
* HbA1c \< 8.5%
* informed consent
* treatment with pre-mixed insulin
* stabile dose of insulin for at least 4 weeks
Exclusion Criteria
* HbA1c \> 8.5 %
* Serum Creatinine \> 1.7 mg/dl
* Alaninaminotranferase or Aspartataminotransferase \> 3x Upper Limit of Normal
* treatment with sulfonylurea or gliptins
* treatment with glitazones
* manifest clinical infections
* treatment with glucocorticoids or antipsychotic drugs
* psychiatric diseases
* alcohol abuse
* myocardial infarction or stroke within the previous 3 months
* surgery within the previous 3 months
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Harald Sourij, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Graz, 8036 Graz, Austria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Graz, Department for Internal Medicine
Graz, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-008486-35
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ENM-DA-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.